# PeptideScanner evidence objects: Abaloparatide

Every published version of the records placed with Abaloparatide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json. Selected public evidence only; not medical advice.

- Objects: 60
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct03512262-abaloparatide-v1"></a>

## ClinicalTrials.gov record NCT03512262

> PeptideScanner retained ClinicalTrials.gov record NCT03512262 at 2026-07-30T19:14:02.186Z. Its registry update date was 2023-04-07, and PeptideScanner's reviewed identity mapping was abaloparatide.

- Evidence object: `story:clinicaltrials-gov-nct03512262-abaloparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-04-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03512262-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct03512262-abaloparatide-v1
- Content SHA-256: `44cb0bbe399562812268491a4038ae78409e3cd6d0a42bbd96ea5b5d3f8b40c8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03512262 ([`ctg-observation-nct03512262-2023-04-07-58f8dd8e8562`](#source-ctg-observation-nct03512262-2023-04-07-58f8dd8e8562))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03512262 at 2026-07-30T19:14:02.186Z. Its registry update date was 2023-04-07, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct03512262-2023-04-07-58f8dd8e8562`](#source-ctg-observation-nct03512262-2023-04-07-58f8dd8e8562))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03512262 at 2026-07-30T19:14:02.186Z. Its registry update date was 2023-04-07, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct03512262-2023-04-07-58f8dd8e8562`](#source-ctg-observation-nct03512262-2023-04-07-58f8dd8e8562))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03512262-2023-04-07-58f8dd8e8562`](#source-ctg-observation-nct03512262-2023-04-07-58f8dd8e8562))

### Sources

<a id="source-ctg-observation-nct03512262-2023-04-07-58f8dd8e8562"></a>
- **ClinicalTrials.gov record NCT03512262 · retained source version 2023-04-07:58f8dd8e8562093fe0617742cd71e1324f5a08ec797c44b5b3da4e04027bcab7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03512262) (`ctg-observation-nct03512262-2023-04-07-58f8dd8e8562`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03512262." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct03512262-abaloparatide-v1 SHA-256: 44cb0bbe399562812268491a4038ae78409e3cd6d0a42bbd96ea5b5d3f8b40c8.

---

<a id="clinicaltrials-gov-nct03710889-abaloparatide-v1"></a>

## ClinicalTrials.gov record NCT03710889

> PeptideScanner retained ClinicalTrials.gov record NCT03710889 at 2026-07-30T19:57:27.406Z. Its registry update date was 2021-10-15, and PeptideScanner's reviewed identity mapping was abaloparatide.

- Evidence object: `story:clinicaltrials-gov-nct03710889-abaloparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-10-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03710889-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct03710889-abaloparatide-v1
- Content SHA-256: `bda0e8bd0f0ab09cdbf36a2aac613bc3861b00c76b1e13e25faf4552de111952`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03710889 ([`ctg-observation-nct03710889-2021-10-15-00dc6cb751da`](#source-ctg-observation-nct03710889-2021-10-15-00dc6cb751da))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03710889 at 2026-07-30T19:57:27.406Z. Its registry update date was 2021-10-15, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct03710889-2021-10-15-00dc6cb751da`](#source-ctg-observation-nct03710889-2021-10-15-00dc6cb751da))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03710889 at 2026-07-30T19:57:27.406Z. Its registry update date was 2021-10-15, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct03710889-2021-10-15-00dc6cb751da`](#source-ctg-observation-nct03710889-2021-10-15-00dc6cb751da))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03710889-2021-10-15-00dc6cb751da`](#source-ctg-observation-nct03710889-2021-10-15-00dc6cb751da))

### Sources

<a id="source-ctg-observation-nct03710889-2021-10-15-00dc6cb751da"></a>
- **ClinicalTrials.gov record NCT03710889 · retained source version 2021-10-15:00dc6cb751da6ed1a768fe880589408a2af9f65f2768ededda4a80fca1931b62** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03710889) (`ctg-observation-nct03710889-2021-10-15-00dc6cb751da`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03710889." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct03710889-abaloparatide-v1 SHA-256: bda0e8bd0f0ab09cdbf36a2aac613bc3861b00c76b1e13e25faf4552de111952.

---

<a id="clinicaltrials-gov-nct03746041-abaloparatide-v1"></a>

## ClinicalTrials.gov record NCT03746041

> PeptideScanner retained ClinicalTrials.gov record NCT03746041 at 2026-07-30T19:17:35.680Z. Its registry update date was 2023-01-23, and PeptideScanner's reviewed identity mapping was abaloparatide.

- Evidence object: `story:clinicaltrials-gov-nct03746041-abaloparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-01-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03746041-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct03746041-abaloparatide-v1
- Content SHA-256: `e5db51197b1f3993a8503e1593d510e80ae38d3715b659a354cff6bcb0c8adee`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03746041 ([`ctg-observation-nct03746041-2023-01-23-cddca69ce77e`](#source-ctg-observation-nct03746041-2023-01-23-cddca69ce77e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03746041 at 2026-07-30T19:17:35.680Z. Its registry update date was 2023-01-23, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct03746041-2023-01-23-cddca69ce77e`](#source-ctg-observation-nct03746041-2023-01-23-cddca69ce77e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03746041 at 2026-07-30T19:17:35.680Z. Its registry update date was 2023-01-23, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct03746041-2023-01-23-cddca69ce77e`](#source-ctg-observation-nct03746041-2023-01-23-cddca69ce77e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03746041-2023-01-23-cddca69ce77e`](#source-ctg-observation-nct03746041-2023-01-23-cddca69ce77e))

### Sources

<a id="source-ctg-observation-nct03746041-2023-01-23-cddca69ce77e"></a>
- **ClinicalTrials.gov record NCT03746041 · retained source version 2023-01-23:cddca69ce77ee5554f5751c0045b9c727c01f584547d611d15e22dfed606620c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03746041) (`ctg-observation-nct03746041-2023-01-23-cddca69ce77e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03746041." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct03746041-abaloparatide-v1 SHA-256: e5db51197b1f3993a8503e1593d510e80ae38d3715b659a354cff6bcb0c8adee.

---

<a id="clinicaltrials-gov-nct03841058-abaloparatide-v1"></a>

## ClinicalTrials.gov record NCT03841058

> PeptideScanner retained ClinicalTrials.gov record NCT03841058 at 2026-07-30T16:20:49.320Z. Its registry update date was 2026-04-28, and PeptideScanner's reviewed identity mapping was abaloparatide.

- Evidence object: `story:clinicaltrials-gov-nct03841058-abaloparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03841058-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct03841058-abaloparatide-v1
- Content SHA-256: `d90f5c21b5a1d5cbb521afa53f7ff124f59b0e63bb91bd71b0f7f72d4f0143ce`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03841058 ([`ctg-observation-nct03841058-2026-04-28-878f8bf410cc`](#source-ctg-observation-nct03841058-2026-04-28-878f8bf410cc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03841058 at 2026-07-30T16:20:49.320Z. Its registry update date was 2026-04-28, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct03841058-2026-04-28-878f8bf410cc`](#source-ctg-observation-nct03841058-2026-04-28-878f8bf410cc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03841058 at 2026-07-30T16:20:49.320Z. Its registry update date was 2026-04-28, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct03841058-2026-04-28-878f8bf410cc`](#source-ctg-observation-nct03841058-2026-04-28-878f8bf410cc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03841058-2026-04-28-878f8bf410cc`](#source-ctg-observation-nct03841058-2026-04-28-878f8bf410cc))

### Sources

<a id="source-ctg-observation-nct03841058-2026-04-28-878f8bf410cc"></a>
- **ClinicalTrials.gov record NCT03841058 · retained source version 2026-04-28:878f8bf410cc1465657beba96cda5f8c11b3e52203dfd76026a6b7cc972c0d78** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03841058) (`ctg-observation-nct03841058-2026-04-28-878f8bf410cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03841058." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct03841058-abaloparatide-v1 SHA-256: d90f5c21b5a1d5cbb521afa53f7ff124f59b0e63bb91bd71b0f7f72d4f0143ce.

---

<a id="clinicaltrials-gov-nct04064411-abaloparatide-v1"></a>

## ClinicalTrials.gov record NCT04064411

> PeptideScanner retained ClinicalTrials.gov record NCT04064411 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-15, and PeptideScanner's reviewed identity mapping was abaloparatide.

- Evidence object: `story:clinicaltrials-gov-nct04064411-abaloparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-02-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04064411-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct04064411-abaloparatide-v1
- Content SHA-256: `fcdfd296db869aeaa4cd61995d4452aa73bb2cb91ee03d29197943e8b71de470`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04064411 ([`ctg-observation-nct04064411-2023-02-15-2de8099e71bb`](#source-ctg-observation-nct04064411-2023-02-15-2de8099e71bb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04064411 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-15, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct04064411-2023-02-15-2de8099e71bb`](#source-ctg-observation-nct04064411-2023-02-15-2de8099e71bb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04064411 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-15, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct04064411-2023-02-15-2de8099e71bb`](#source-ctg-observation-nct04064411-2023-02-15-2de8099e71bb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04064411-2023-02-15-2de8099e71bb`](#source-ctg-observation-nct04064411-2023-02-15-2de8099e71bb))

### Sources

<a id="source-ctg-observation-nct04064411-2023-02-15-2de8099e71bb"></a>
- **ClinicalTrials.gov record NCT04064411 · retained source version 2023-02-15:2de8099e71bb8b25709a1e70af99bea80dbd8034b3340592feff24ef551e26ba** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04064411) (`ctg-observation-nct04064411-2023-02-15-2de8099e71bb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04064411." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct04064411-abaloparatide-v1 SHA-256: fcdfd296db869aeaa4cd61995d4452aa73bb2cb91ee03d29197943e8b71de470.

---

<a id="clinicaltrials-gov-nct04167163-abaloparatide-v1"></a>

## ClinicalTrials.gov record NCT04167163

> PeptideScanner retained ClinicalTrials.gov record NCT04167163 at 2026-07-30T16:19:03.051Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was abaloparatide.

- Evidence object: `story:clinicaltrials-gov-nct04167163-abaloparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04167163-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct04167163-abaloparatide-v1
- Content SHA-256: `7fda969d3b31dfc3aaa37a6717d6778f01a3227270199b869466b451217d8a19`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04167163 ([`ctg-observation-nct04167163-2026-06-05-4701baaec736`](#source-ctg-observation-nct04167163-2026-06-05-4701baaec736))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04167163 at 2026-07-30T16:19:03.051Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct04167163-2026-06-05-4701baaec736`](#source-ctg-observation-nct04167163-2026-06-05-4701baaec736))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04167163 at 2026-07-30T16:19:03.051Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct04167163-2026-06-05-4701baaec736`](#source-ctg-observation-nct04167163-2026-06-05-4701baaec736))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04167163-2026-06-05-4701baaec736`](#source-ctg-observation-nct04167163-2026-06-05-4701baaec736))

### Sources

<a id="source-ctg-observation-nct04167163-2026-06-05-4701baaec736"></a>
- **ClinicalTrials.gov record NCT04167163 · retained source version 2026-06-05:4701baaec73635fa789d2ef70899f44d5f0df314cb6175e53f9a5e9379badc86** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04167163) (`ctg-observation-nct04167163-2026-06-05-4701baaec736`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04167163." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct04167163-abaloparatide-v1 SHA-256: 7fda969d3b31dfc3aaa37a6717d6778f01a3227270199b869466b451217d8a19.

---

<a id="clinicaltrials-gov-nct04249232-abaloparatide-v1"></a>

## ClinicalTrials.gov record NCT04249232

> PeptideScanner retained ClinicalTrials.gov record NCT04249232 at 2026-07-30T18:43:56.172Z. Its registry update date was 2024-06-14, and PeptideScanner's reviewed identity mapping was abaloparatide.

- Evidence object: `story:clinicaltrials-gov-nct04249232-abaloparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-06-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04249232-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct04249232-abaloparatide-v1
- Content SHA-256: `6a14203609e837df315bdef530cd5cc586d44fd8cdb012829a410638d89db3fb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04249232 ([`ctg-observation-nct04249232-2024-06-14-27d62f40eb77`](#source-ctg-observation-nct04249232-2024-06-14-27d62f40eb77))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04249232 at 2026-07-30T18:43:56.172Z. Its registry update date was 2024-06-14, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct04249232-2024-06-14-27d62f40eb77`](#source-ctg-observation-nct04249232-2024-06-14-27d62f40eb77))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04249232 at 2026-07-30T18:43:56.172Z. Its registry update date was 2024-06-14, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct04249232-2024-06-14-27d62f40eb77`](#source-ctg-observation-nct04249232-2024-06-14-27d62f40eb77))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04249232-2024-06-14-27d62f40eb77`](#source-ctg-observation-nct04249232-2024-06-14-27d62f40eb77))

### Sources

<a id="source-ctg-observation-nct04249232-2024-06-14-27d62f40eb77"></a>
- **ClinicalTrials.gov record NCT04249232 · retained source version 2024-06-14:27d62f40eb77435b0862274d68fb91fc410724a02e4b64f90a9b11e504420168** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04249232) (`ctg-observation-nct04249232-2024-06-14-27d62f40eb77`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04249232." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct04249232-abaloparatide-v1 SHA-256: 6a14203609e837df315bdef530cd5cc586d44fd8cdb012829a410638d89db3fb.

---

<a id="clinicaltrials-gov-nct04467983-abaloparatide-v1"></a>

## ClinicalTrials.gov record NCT04467983

> PeptideScanner retained ClinicalTrials.gov record NCT04467983 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-08, and PeptideScanner's reviewed identity mapping was abaloparatide.

- Evidence object: `story:clinicaltrials-gov-nct04467983-abaloparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04467983-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct04467983-abaloparatide-v1
- Content SHA-256: `751122abe8b48cb6b66f9739ae9cb38b31f5f36d696f79b1d80a8cec7c8ddc12`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04467983 ([`ctg-observation-nct04467983-2026-06-08-2545958f752a`](#source-ctg-observation-nct04467983-2026-06-08-2545958f752a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04467983 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-08, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct04467983-2026-06-08-2545958f752a`](#source-ctg-observation-nct04467983-2026-06-08-2545958f752a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04467983 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-08, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct04467983-2026-06-08-2545958f752a`](#source-ctg-observation-nct04467983-2026-06-08-2545958f752a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04467983-2026-06-08-2545958f752a`](#source-ctg-observation-nct04467983-2026-06-08-2545958f752a))

### Sources

<a id="source-ctg-observation-nct04467983-2026-06-08-2545958f752a"></a>
- **ClinicalTrials.gov record NCT04467983 · retained source version 2026-06-08:2545958f752a55b8b5dde100012de94fab7f2feb82687c062a0e25a12cf82906** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04467983) (`ctg-observation-nct04467983-2026-06-08-2545958f752a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04467983." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct04467983-abaloparatide-v1 SHA-256: 751122abe8b48cb6b66f9739ae9cb38b31f5f36d696f79b1d80a8cec7c8ddc12.

---

<a id="clinicaltrials-gov-nct07587775-abaloparatide-v1"></a>

## ClinicalTrials.gov record NCT07587775

> PeptideScanner retained ClinicalTrials.gov record NCT07587775 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was abaloparatide.

- Evidence object: `story:clinicaltrials-gov-nct07587775-abaloparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-23
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07587775-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct07587775-abaloparatide-v1
- Content SHA-256: `c5dc148625d7add3672d17b36c9c50da80afb95c07a1b42283e74050143b7e2a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07587775 ([`ctg-observation-nct07587775-2026-07-23-361b31697cb0`](#source-ctg-observation-nct07587775-2026-07-23-361b31697cb0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07587775 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct07587775-2026-07-23-361b31697cb0`](#source-ctg-observation-nct07587775-2026-07-23-361b31697cb0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07587775 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct07587775-2026-07-23-361b31697cb0`](#source-ctg-observation-nct07587775-2026-07-23-361b31697cb0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07587775-2026-07-23-361b31697cb0`](#source-ctg-observation-nct07587775-2026-07-23-361b31697cb0))

### Sources

<a id="source-ctg-observation-nct07587775-2026-07-23-361b31697cb0"></a>
- **ClinicalTrials.gov record NCT07587775 · retained source version 2026-07-23:361b31697cb09442280d5f09ce8fbf1c9a2f23a962fd9a89ac1711a72e2f5040** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07587775) (`ctg-observation-nct07587775-2026-07-23-361b31697cb0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07587775." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#clinicaltrials-gov-nct07587775-abaloparatide-v1 SHA-256: c5dc148625d7add3672d17b36c9c50da80afb95c07a1b42283e74050143b7e2a.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v10-v1"></a>

## Abaloparatide DailyMed SPL version 10

> DailyMed lists Structured Product Labeling version 10 for the reviewed Abaloparatide label family with a published date of 2021-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v10:v1`
- Evidence domain: Regulatory
- Date in source: 2021-12-30
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v10/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v10-v1
- Content SHA-256: `69715936c597c70466de2ae743d188015b57f83dad55169ee1cde04168e3f63f`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 10 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v10-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v10-history))

#### Summary

DailyMed lists Structured Product Labeling version 10 for the reviewed Abaloparatide label family with a published date of 2021-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v10-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v10-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 10 for the reviewed Abaloparatide label family with a published date of 2021-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v10-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v10-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v10-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v10-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v10-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 10 · published 2021-12-30 · retained ZIP SHA-256 bf560cef16b29f47dfff0663923b79cb4a7a968b17719a4ab78b0766c06d5fe2** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=10) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v10-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 10." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v10-v1 SHA-256: 69715936c597c70466de2ae743d188015b57f83dad55169ee1cde04168e3f63f.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v11-v1"></a>

## Abaloparatide DailyMed SPL version 11

> DailyMed lists Structured Product Labeling version 11 for the reviewed Abaloparatide label family with a published date of 2022-11-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v11:v1`
- Evidence domain: Regulatory
- Date in source: 2022-11-10
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v11/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v11-v1
- Content SHA-256: `1207b0d1964cb7e734c9d4df49c9e3296d1a0ef4ef3eb414853475c157967c99`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 11 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v11-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v11-history))

#### Summary

DailyMed lists Structured Product Labeling version 11 for the reviewed Abaloparatide label family with a published date of 2022-11-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v11-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v11-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 11 for the reviewed Abaloparatide label family with a published date of 2022-11-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v11-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v11-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v11-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v11-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v11-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 11 · published 2022-11-10 · retained ZIP SHA-256 402fc7a16f5b307d929b7d1a6fd701d7f4a5d7a14537000e6fdec66b1e7960b1** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=11) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v11-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 11." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v11-v1 SHA-256: 1207b0d1964cb7e734c9d4df49c9e3296d1a0ef4ef3eb414853475c157967c99.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v12-v1"></a>

## Abaloparatide DailyMed SPL version 12

> DailyMed lists Structured Product Labeling version 12 for the reviewed Abaloparatide label family with a published date of 2022-12-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v12:v1`
- Evidence domain: Regulatory
- Date in source: 2022-12-28
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v12/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v12-v1
- Content SHA-256: `24c4ab97663f8ed5c1c59aa096e6d0565927f8c5de3e807ce62606d9cca8bdca`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 12 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v12-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v12-history))

#### Summary

DailyMed lists Structured Product Labeling version 12 for the reviewed Abaloparatide label family with a published date of 2022-12-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v12-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v12-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 12 for the reviewed Abaloparatide label family with a published date of 2022-12-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v12-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v12-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v12-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v12-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v12-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 12 · published 2022-12-28 · retained ZIP SHA-256 2d4cc3b18c2c2ac8d4dd2ba5f4ccd8ae5a9388775491843f7303501de3600fdc** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=12) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v12-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 12." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v12-v1 SHA-256: 24c4ab97663f8ed5c1c59aa096e6d0565927f8c5de3e807ce62606d9cca8bdca.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v13-v1"></a>

## Abaloparatide DailyMed SPL version 13

> DailyMed lists Structured Product Labeling version 13 for the reviewed Abaloparatide label family with a published date of 2023-06-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v13:v1`
- Evidence domain: Regulatory
- Date in source: 2023-06-28
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v13/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v13-v1
- Content SHA-256: `18699feb8a6de7a1621d6fa956e42933265c11049391c1a682c94564783b49cc`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 13 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v13-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v13-history))

#### Summary

DailyMed lists Structured Product Labeling version 13 for the reviewed Abaloparatide label family with a published date of 2023-06-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v13-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v13-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 13 for the reviewed Abaloparatide label family with a published date of 2023-06-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v13-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v13-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v13-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v13-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v13-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 13 · published 2023-06-28 · retained ZIP SHA-256 e1f9923bcd383aad992fb407b4cea0be2ed26ca070888ee8b240ec57f0253bd0** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=13) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v13-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 13." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v13-v1 SHA-256: 18699feb8a6de7a1621d6fa956e42933265c11049391c1a682c94564783b49cc.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v15-v1"></a>

## Abaloparatide DailyMed SPL version 15

> DailyMed lists Structured Product Labeling version 15 for the reviewed Abaloparatide label family with a published date of 2023-11-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v15:v1`
- Evidence domain: Regulatory
- Date in source: 2023-11-30
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v15/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v15-v1
- Content SHA-256: `a0ba2ef1cd17f55a54f7a1113ea9fcf2eee526d8452a03176502919f9f593e05`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 15 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v15-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v15-history))

#### Summary

DailyMed lists Structured Product Labeling version 15 for the reviewed Abaloparatide label family with a published date of 2023-11-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v15-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v15-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 15 for the reviewed Abaloparatide label family with a published date of 2023-11-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v15-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v15-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v15-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v15-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v15-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 15 · published 2023-11-30 · retained ZIP SHA-256 6dc69e27f779d9805f5c8c07d5d99f86b60f2640b0bf2a88fe1843b45c3ade15** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=15) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v15-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 15." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v15-v1 SHA-256: a0ba2ef1cd17f55a54f7a1113ea9fcf2eee526d8452a03176502919f9f593e05.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v16-v1"></a>

## Abaloparatide DailyMed SPL version 16

> DailyMed lists Structured Product Labeling version 16 for the reviewed Abaloparatide label family with a published date of 2024-03-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v16:v1`
- Evidence domain: Regulatory
- Date in source: 2024-03-08
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v16/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v16-v1
- Content SHA-256: `719294ba83c3615b0a7485d4940a636e03d737b08748e170ba440a9346ae1f84`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 16 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v16-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v16-history))

#### Summary

DailyMed lists Structured Product Labeling version 16 for the reviewed Abaloparatide label family with a published date of 2024-03-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v16-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v16-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 16 for the reviewed Abaloparatide label family with a published date of 2024-03-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v16-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v16-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v16-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v16-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v16-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 16 · published 2024-03-08 · retained ZIP SHA-256 d99a372f47d481deb482f99b18b52b9b66efa84ddede1095e1e9fda7da3a4bf3** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=16) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v16-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 16." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v16-v1 SHA-256: 719294ba83c3615b0a7485d4940a636e03d737b08748e170ba440a9346ae1f84.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18-v1"></a>

## Abaloparatide DailyMed SPL version 18

> DailyMed lists Structured Product Labeling version 18 for the reviewed Abaloparatide label family with a published date of 2025-04-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18:v1`
- Evidence domain: Regulatory
- Date in source: 2025-04-11
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18-v1
- Content SHA-256: `7353ee95a5e55e60afda5ab6ecb72b5156a3e4ae760debba05cfb03c4ee1884e`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 18 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18-history))

#### Summary

DailyMed lists Structured Product Labeling version 18 for the reviewed Abaloparatide label family with a published date of 2025-04-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 18 for the reviewed Abaloparatide label family with a published date of 2025-04-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 18 · published 2025-04-11 · retained ZIP SHA-256 bda05a2d8f2eba0784790ffac71bf561542f8fddb148fd4805a63f1798b5d5cd** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=18) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 18." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18-v1 SHA-256: 7353ee95a5e55e60afda5ab6ecb72b5156a3e4ae760debba05cfb03c4ee1884e.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19-v1"></a>

## Abaloparatide DailyMed SPL version 19

> DailyMed lists Structured Product Labeling version 19 for the reviewed Abaloparatide label family with a published date of 2026-08-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19:v1`
- Evidence domain: Regulatory
- Date in source: 2026-08-17
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19-v1
- Content SHA-256: `8360144e0d5d0c11332302e376d0a71f7d72403a278baccba7885e1a522dc405`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 19 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19-history))

#### Summary

DailyMed lists Structured Product Labeling version 19 for the reviewed Abaloparatide label family with a published date of 2026-08-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 19 for the reviewed Abaloparatide label family with a published date of 2026-08-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 19 · published 2026-08-17 · retained ZIP SHA-256 0972d261dcba3ae48d54920e976a32e45e2f7b9f8c2f3458dd827ca900db9c44** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=19) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 19." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19-v1 SHA-256: 8360144e0d5d0c11332302e376d0a71f7d72403a278baccba7885e1a522dc405.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v1-v1"></a>

## Abaloparatide DailyMed SPL version 1

> DailyMed lists Structured Product Labeling version 1 for the reviewed Abaloparatide label family with a published date of 2017-05-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v1:v1`
- Evidence domain: Regulatory
- Date in source: 2017-05-04
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v1-v1
- Content SHA-256: `355b1a933194496f50f13db7cad563a0678afee7c46690ba8794e22980a6b9c6`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 1 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v1-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v1-history))

#### Summary

DailyMed lists Structured Product Labeling version 1 for the reviewed Abaloparatide label family with a published date of 2017-05-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v1-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v1-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 1 for the reviewed Abaloparatide label family with a published date of 2017-05-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v1-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v1-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v1-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v1-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v1-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 1 · published 2017-05-04 · retained ZIP SHA-256 1e823246f800a2ba662c6601071ed4c3db5860ede1f4f3e94472214e68e8ff8a** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=1) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v1-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 1." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v1-v1 SHA-256: 355b1a933194496f50f13db7cad563a0678afee7c46690ba8794e22980a6b9c6.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v2-v1"></a>

## Abaloparatide DailyMed SPL version 2

> DailyMed lists Structured Product Labeling version 2 for the reviewed Abaloparatide label family with a published date of 2017-10-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v2:v1`
- Evidence domain: Regulatory
- Date in source: 2017-10-10
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v2/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v2-v1
- Content SHA-256: `9d69e3fdfa3980718ae04b16dee5ad6b32b3d78e22667a49d53b5ca5f3400a03`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 2 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v2-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v2-history))

#### Summary

DailyMed lists Structured Product Labeling version 2 for the reviewed Abaloparatide label family with a published date of 2017-10-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v2-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v2-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 2 for the reviewed Abaloparatide label family with a published date of 2017-10-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v2-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v2-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v2-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v2-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v2-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 2 · published 2017-10-10 · retained ZIP SHA-256 da4788c4a702a59356794141ba4cfde432f928a9c367496deeb1fbdd38043e5e** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=2) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v2-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 2." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v2-v1 SHA-256: 9d69e3fdfa3980718ae04b16dee5ad6b32b3d78e22667a49d53b5ca5f3400a03.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v4-v1"></a>

## Abaloparatide DailyMed SPL version 4

> DailyMed lists Structured Product Labeling version 4 for the reviewed Abaloparatide label family with a published date of 2018-07-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v4:v1`
- Evidence domain: Regulatory
- Date in source: 2018-07-27
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v4/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v4-v1
- Content SHA-256: `99c4e4fdc47ba1a6870412cbac31085955e79f71ad32117767cdc7436c9eae8f`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 4 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v4-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v4-history))

#### Summary

DailyMed lists Structured Product Labeling version 4 for the reviewed Abaloparatide label family with a published date of 2018-07-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v4-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v4-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 4 for the reviewed Abaloparatide label family with a published date of 2018-07-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v4-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v4-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v4-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v4-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v4-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 4 · published 2018-07-27 · retained ZIP SHA-256 babcd8d2ee555482dc85e9d76ba12205e837d018d988c8e5722de78bcb9554b4** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=4) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v4-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 4." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v4-v1 SHA-256: 99c4e4fdc47ba1a6870412cbac31085955e79f71ad32117767cdc7436c9eae8f.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v5-v1"></a>

## Abaloparatide DailyMed SPL version 5

> DailyMed lists Structured Product Labeling version 5 for the reviewed Abaloparatide label family with a published date of 2018-11-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v5:v1`
- Evidence domain: Regulatory
- Date in source: 2018-11-01
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v5/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v5-v1
- Content SHA-256: `caaaefa55689db92f2b92a6629e28fb1ffb36ea83b02578bc264e0c3eb833d59`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 5 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v5-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v5-history))

#### Summary

DailyMed lists Structured Product Labeling version 5 for the reviewed Abaloparatide label family with a published date of 2018-11-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v5-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v5-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 5 for the reviewed Abaloparatide label family with a published date of 2018-11-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v5-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v5-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v5-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v5-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v5-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 5 · published 2018-11-01 · retained ZIP SHA-256 ccdf5508bdf9262f56024ca6abbb131ba327f56b7a60d913e90fced743e7e7fc** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=5) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v5-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 5." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v5-v1 SHA-256: caaaefa55689db92f2b92a6629e28fb1ffb36ea83b02578bc264e0c3eb833d59.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v6-v1"></a>

## Abaloparatide DailyMed SPL version 6

> DailyMed lists Structured Product Labeling version 6 for the reviewed Abaloparatide label family with a published date of 2019-11-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v6:v1`
- Evidence domain: Regulatory
- Date in source: 2019-11-26
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v6/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v6-v1
- Content SHA-256: `027b2e7ec8d600c3e6704e4fd8586885c964b9b6e449fc5626fecf8f434e2840`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 6 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v6-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v6-history))

#### Summary

DailyMed lists Structured Product Labeling version 6 for the reviewed Abaloparatide label family with a published date of 2019-11-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v6-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v6-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 6 for the reviewed Abaloparatide label family with a published date of 2019-11-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v6-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v6-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v6-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v6-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v6-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 6 · published 2019-11-26 · retained ZIP SHA-256 11f0a626b27e476d39be84bf349947444086d4da9f64cdfaf986bb4b6fa14e3f** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=6) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v6-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 6." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v6-v1 SHA-256: 027b2e7ec8d600c3e6704e4fd8586885c964b9b6e449fc5626fecf8f434e2840.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v7-v1"></a>

## Abaloparatide DailyMed SPL version 7

> DailyMed lists Structured Product Labeling version 7 for the reviewed Abaloparatide label family with a published date of 2020-11-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v7:v1`
- Evidence domain: Regulatory
- Date in source: 2020-11-06
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v7/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v7-v1
- Content SHA-256: `26433c50e955d000ff6babeafe0fe7885a3ff41eb757f55a3d0ffa968ffffed3`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 7 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v7-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v7-history))

#### Summary

DailyMed lists Structured Product Labeling version 7 for the reviewed Abaloparatide label family with a published date of 2020-11-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v7-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v7-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 7 for the reviewed Abaloparatide label family with a published date of 2020-11-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v7-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v7-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v7-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v7-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v7-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 7 · published 2020-11-06 · retained ZIP SHA-256 26cfa3aea6698db72912be4addf86b4a56bb482cdb60191455e15ef6b69831f9** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=7) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v7-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 7." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v7-v1 SHA-256: 26433c50e955d000ff6babeafe0fe7885a3ff41eb757f55a3d0ffa968ffffed3.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v8-v1"></a>

## Abaloparatide DailyMed SPL version 8

> DailyMed lists Structured Product Labeling version 8 for the reviewed Abaloparatide label family with a published date of 2021-05-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v8:v1`
- Evidence domain: Regulatory
- Date in source: 2021-05-17
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v8/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v8-v1
- Content SHA-256: `353c4d9a8db63653cb45c92207d32399463141201aea68c410e91fc5184657cc`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 8 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v8-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v8-history))

#### Summary

DailyMed lists Structured Product Labeling version 8 for the reviewed Abaloparatide label family with a published date of 2021-05-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v8-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v8-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 8 for the reviewed Abaloparatide label family with a published date of 2021-05-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v8-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v8-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v8-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v8-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v8-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 8 · published 2021-05-17 · retained ZIP SHA-256 35f56bfa6ef97ade088442847a28b57677282f91bf65c545a3f6f6ecf786e2fd** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=8) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v8-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 8." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v8-v1 SHA-256: 353c4d9a8db63653cb45c92207d32399463141201aea68c410e91fc5184657cc.

---

<a id="dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v9-v1"></a>

## Abaloparatide DailyMed SPL version 9

> DailyMed lists Structured Product Labeling version 9 for the reviewed Abaloparatide label family with a published date of 2021-09-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v9:v1`
- Evidence domain: Regulatory
- Date in source: 2021-09-29
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v9/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v9-v1
- Content SHA-256: `1cdc4d1fbdac5eba4479427e964faf50381c8bf8c339f95d098401d918c7b168`

### Claims and source pins

#### Headline

Abaloparatide DailyMed SPL version 9 ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v9-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v9-history))

#### Summary

DailyMed lists Structured Product Labeling version 9 for the reviewed Abaloparatide label family with a published date of 2021-09-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v9-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v9-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 9 for the reviewed Abaloparatide label family with a published date of 2021-09-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v9-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v9-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v9-history`](#source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v9-history))

### Sources

<a id="source-dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v9-history"></a>
- **DailyMed SPL SET ID 712143d9-e21e-4013-bb3b-3426a21060a8 · SPL version 9 · published 2021-09-29 · retained ZIP SHA-256 323143fe34fe82123b6daaead3c3e14b468f08fe4a163729880edaf2bb8921a1** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=9) (`dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v9-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide DailyMed SPL version 9." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#dailymed-label-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v9-v1 SHA-256: 1cdc4d1fbdac5eba4479427e964faf50381c8bf8c339f95d098401d918c7b168.

---

<a id="fda-drugs-nda208743-v1"></a>

## Drugs@FDA application NDA208743

> The official Drugs@FDA dataset lists original submission 1 for NDA 208743 with status AP dated 2017-04-28, and names abaloparatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda208743:v1`
- Evidence domain: Regulatory
- Date in source: 2017-04-28
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda208743/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#fda-drugs-nda208743-v1
- Content SHA-256: `81fad6dd989c4d3f4584da69d08c40c8d30fe73ff959983a1703bd4de9f48077`

### Claims and source pins

#### Headline

Drugs@FDA application NDA208743 ([`fda-drugs-nda208743-2017-04-28-566de3ccde8d`](#source-fda-drugs-nda208743-2017-04-28-566de3ccde8d))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 208743 with status AP dated 2017-04-28, and names abaloparatide among the application record's active ingredients. ([`fda-drugs-nda208743-2017-04-28-566de3ccde8d`](#source-fda-drugs-nda208743-2017-04-28-566de3ccde8d))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 208743 with status AP dated 2017-04-28, and names abaloparatide among the application record's active ingredients. ([`fda-drugs-nda208743-2017-04-28-566de3ccde8d`](#source-fda-drugs-nda208743-2017-04-28-566de3ccde8d))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda208743-2017-04-28-566de3ccde8d`](#source-fda-drugs-nda208743-2017-04-28-566de3ccde8d))

### Sources

<a id="source-fda-drugs-nda208743-2017-04-28-566de3ccde8d"></a>
- **Drugs@FDA application NDA208743 · original submission status AP · 2017-04-28 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA208743%22&limit=1) (`fda-drugs-nda208743-2017-04-28-566de3ccde8d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA208743." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#fda-drugs-nda208743-v1 SHA-256: 81fad6dd989c4d3f4584da69d08c40c8d30fe73ff959983a1703bd4de9f48077.

---

<a id="federal-register-2018-22956-v1"></a>

## Federal Register notice 2018-22956

> The Federal Register published notice 2018-22956, attributed to FDA and its parent HHS department, on 2018-10-22. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TYMLOS,” and PeptideScanner's exact reviewed identity mapping connects the document to Abaloparatide.

- Evidence object: `story:federal-register-2018-22956:v1`
- Evidence domain: Regulatory
- Date in source: 2018-10-22
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2018-22956/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#federal-register-2018-22956-v1
- Content SHA-256: `80cd525b3b6f0ba01800e1725f89abdc7f6b0903ce65e2e0ef208fe91da464ed`

### Claims and source pins

#### Headline

Federal Register notice 2018-22956 ([`federal-register-2018-22956-0dad4c1d8b40`](#source-federal-register-2018-22956-0dad4c1d8b40))

#### Summary

The Federal Register published notice 2018-22956, attributed to FDA and its parent HHS department, on 2018-10-22. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TYMLOS,” and PeptideScanner's exact reviewed identity mapping connects the document to Abaloparatide. ([`federal-register-2018-22956-0dad4c1d8b40`](#source-federal-register-2018-22956-0dad4c1d8b40))

#### Paragraph 1

The Federal Register published notice 2018-22956, attributed to FDA and its parent HHS department, on 2018-10-22. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TYMLOS,” and PeptideScanner's exact reviewed identity mapping connects the document to Abaloparatide. ([`federal-register-2018-22956-0dad4c1d8b40`](#source-federal-register-2018-22956-0dad4c1d8b40))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2018-22956-0dad4c1d8b40`](#source-federal-register-2018-22956-0dad4c1d8b40))

### Sources

<a id="source-federal-register-2018-22956-0dad4c1d8b40"></a>
- **Federal Register notice 2018-22956 · published 2018-10-22 · Determination of Regulatory Review Period for Purposes of Patent Extension; TYMLOS** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2018-10-22/pdf/2018-22956.pdf) (`federal-register-2018-22956-0dad4c1d8b40`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2018-22956." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#federal-register-2018-22956-v1 SHA-256: 80cd525b3b6f0ba01800e1725f89abdc7f6b0903ce65e2e0ef208fe91da464ed.

---

<a id="pubmed-pmid-25987981-abaloparatide-v1"></a>

## Abaloparatide: a new anabolic therapy on the horizon.

> PubMed lists PMID 25987981 in BoneKEy reports as Journal Article, with publication-date metadata of 2015-04-29 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25987981-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25987981-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-25987981-abaloparatide-v1
- Content SHA-256: `af2634199cff8760906c9b1b8234eb8d4236de8269da4fc2ae4dc8c055133371`

### Claims and source pins

#### Headline

Abaloparatide: a new anabolic therapy on the horizon. ([`pubmed-observation-pmid-25987981-2022-03-09-526e04574c42`](#source-pubmed-observation-pmid-25987981-2022-03-09-526e04574c42))

#### Summary

PubMed lists PMID 25987981 in BoneKEy reports as Journal Article, with publication-date metadata of 2015-04-29 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25987981-2022-03-09-526e04574c42`](#source-pubmed-observation-pmid-25987981-2022-03-09-526e04574c42))

#### Paragraph 1

PubMed lists PMID 25987981 in BoneKEy reports as Journal Article, with publication-date metadata of 2015-04-29 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25987981-2022-03-09-526e04574c42`](#source-pubmed-observation-pmid-25987981-2022-03-09-526e04574c42))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25987981-2022-03-09-526e04574c42`](#source-pubmed-observation-pmid-25987981-2022-03-09-526e04574c42))

### Sources

<a id="source-pubmed-observation-pmid-25987981-2022-03-09-526e04574c42"></a>
- **Abaloparatide: a new anabolic therapy on the horizon. · retained source version 1:2022-03-09:current:526e04574c420a20b3f41b1d39b683cb45e4425e19ae99d90daaa9082580b766** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25987981/) (`pubmed-observation-pmid-25987981-2022-03-09-526e04574c42`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide: a new anabolic therapy on the horizon." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-25987981-abaloparatide-v1 SHA-256: af2634199cff8760906c9b1b8234eb8d4236de8269da4fc2ae4dc8c055133371.

---

<a id="pubmed-pmid-26562265-abaloparatide-v1"></a>

## PubMed record PMID 26562265

> PeptideScanner retained PubMed bibliographic metadata for PMID 26562265 at 2026-07-30T21:09:17.736Z. PubMed recorded a metadata revision date of 2018-11-13 and an Entrez history date of 2015-11-13. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-26562265-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26562265-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-26562265-abaloparatide-v1
- Content SHA-256: `bdc2ee19b7abbb483d0e4260e5d0952b041e93a10e52eaaed7a043977cb3bb10`

### Claims and source pins

#### Headline

PubMed record PMID 26562265 ([`pubmed-observation-pmid-26562265-2018-11-13-69af09569be9`](#source-pubmed-observation-pmid-26562265-2018-11-13-69af09569be9))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 26562265 at 2026-07-30T21:09:17.736Z. PubMed recorded a metadata revision date of 2018-11-13 and an Entrez history date of 2015-11-13. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-26562265-2018-11-13-69af09569be9`](#source-pubmed-observation-pmid-26562265-2018-11-13-69af09569be9))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 26562265 at 2026-07-30T21:09:17.736Z. PubMed recorded a metadata revision date of 2018-11-13 and an Entrez history date of 2015-11-13. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-26562265-2018-11-13-69af09569be9`](#source-pubmed-observation-pmid-26562265-2018-11-13-69af09569be9))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26562265-2018-11-13-69af09569be9`](#source-pubmed-observation-pmid-26562265-2018-11-13-69af09569be9))

### Sources

<a id="source-pubmed-observation-pmid-26562265-2018-11-13-69af09569be9"></a>
- **PubMed record PMID 26562265 · retained source version 1:2018-11-13:current:69af09569be9414cd1d2823309db844c6a44558553bbd187e1ebe14437004d2f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26562265/) (`pubmed-observation-pmid-26562265-2018-11-13-69af09569be9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 26562265." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-26562265-abaloparatide-v1 SHA-256: bdc2ee19b7abbb483d0e4260e5d0952b041e93a10e52eaaed7a043977cb3bb10.

---

<a id="pubmed-pmid-27395059-abaloparatide-v1"></a>

## PubMed record PMID 27395059

> PeptideScanner retained PubMed bibliographic metadata for PMID 27395059 at 2026-07-30T21:09:22.204Z. PubMed recorded a metadata revision date of 2018-11-13 and an Entrez history date of 2016-07-11. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-27395059-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27395059-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-27395059-abaloparatide-v1
- Content SHA-256: `089dc24bc4af3a1d47e97f975d6850d3e6041c5eb1f09c35ade98d0bca32e34a`

### Claims and source pins

#### Headline

PubMed record PMID 27395059 ([`pubmed-observation-pmid-27395059-2018-11-13-0864cbb65b5a`](#source-pubmed-observation-pmid-27395059-2018-11-13-0864cbb65b5a))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 27395059 at 2026-07-30T21:09:22.204Z. PubMed recorded a metadata revision date of 2018-11-13 and an Entrez history date of 2016-07-11. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27395059-2018-11-13-0864cbb65b5a`](#source-pubmed-observation-pmid-27395059-2018-11-13-0864cbb65b5a))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 27395059 at 2026-07-30T21:09:22.204Z. PubMed recorded a metadata revision date of 2018-11-13 and an Entrez history date of 2016-07-11. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27395059-2018-11-13-0864cbb65b5a`](#source-pubmed-observation-pmid-27395059-2018-11-13-0864cbb65b5a))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27395059-2018-11-13-0864cbb65b5a`](#source-pubmed-observation-pmid-27395059-2018-11-13-0864cbb65b5a))

### Sources

<a id="source-pubmed-observation-pmid-27395059-2018-11-13-0864cbb65b5a"></a>
- **PubMed record PMID 27395059 · retained source version 1:2018-11-13:current:0864cbb65b5aa09a7953dc648e46e1f7da9ea35fbdc79f548473347bd4bf4eb7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27395059/) (`pubmed-observation-pmid-27395059-2018-11-13-0864cbb65b5a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 27395059." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-27395059-abaloparatide-v1 SHA-256: 089dc24bc4af3a1d47e97f975d6850d3e6041c5eb1f09c35ade98d0bca32e34a.

---

<a id="pubmed-pmid-27612281-abaloparatide-v1"></a>

## PubMed record PMID 27612281

> PeptideScanner retained PubMed bibliographic metadata for PMID 27612281 at 2026-07-30T21:09:23.525Z. PubMed recorded a metadata revision date of 2018-10-15 and an Entrez history date of 2016-09-10. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-27612281-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-10-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27612281-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-27612281-abaloparatide-v1
- Content SHA-256: `98c9a9504352cdfb9644050a19df2909fe396f490f9e55df79844b51be377ec0`

### Claims and source pins

#### Headline

PubMed record PMID 27612281 ([`pubmed-observation-pmid-27612281-2018-10-15-31a69c68d513`](#source-pubmed-observation-pmid-27612281-2018-10-15-31a69c68d513))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 27612281 at 2026-07-30T21:09:23.525Z. PubMed recorded a metadata revision date of 2018-10-15 and an Entrez history date of 2016-09-10. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27612281-2018-10-15-31a69c68d513`](#source-pubmed-observation-pmid-27612281-2018-10-15-31a69c68d513))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 27612281 at 2026-07-30T21:09:23.525Z. PubMed recorded a metadata revision date of 2018-10-15 and an Entrez history date of 2016-09-10. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27612281-2018-10-15-31a69c68d513`](#source-pubmed-observation-pmid-27612281-2018-10-15-31a69c68d513))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27612281-2018-10-15-31a69c68d513`](#source-pubmed-observation-pmid-27612281-2018-10-15-31a69c68d513))

### Sources

<a id="source-pubmed-observation-pmid-27612281-2018-10-15-31a69c68d513"></a>
- **PubMed record PMID 27612281 · retained source version 1:2018-10-15:current:31a69c68d513da23f45a1b7cb528dc2ac10be45e9c17f48c7464991c8a753953** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27612281/) (`pubmed-observation-pmid-27612281-2018-10-15-31a69c68d513`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 27612281." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-27612281-abaloparatide-v1 SHA-256: 98c9a9504352cdfb9644050a19df2909fe396f490f9e55df79844b51be377ec0.

---

<a id="pubmed-pmid-27748532-abaloparatide-v1"></a>

## PubMed record PMID 27748532

> PeptideScanner retained PubMed bibliographic metadata for PMID 27748532 at 2026-07-30T21:09:23.546Z. PubMed recorded a metadata revision date of 2018-10-15 and an Entrez history date of 2016-10-18. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-27748532-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-10-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27748532-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-27748532-abaloparatide-v1
- Content SHA-256: `545bf3ab9d3e4f2d7b880430de0590d866cecc3adeead5f1bfd8b2733dfa39e2`

### Claims and source pins

#### Headline

PubMed record PMID 27748532 ([`pubmed-observation-pmid-27748532-2018-10-15-aebb0330f817`](#source-pubmed-observation-pmid-27748532-2018-10-15-aebb0330f817))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 27748532 at 2026-07-30T21:09:23.546Z. PubMed recorded a metadata revision date of 2018-10-15 and an Entrez history date of 2016-10-18. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27748532-2018-10-15-aebb0330f817`](#source-pubmed-observation-pmid-27748532-2018-10-15-aebb0330f817))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 27748532 at 2026-07-30T21:09:23.546Z. PubMed recorded a metadata revision date of 2018-10-15 and an Entrez history date of 2016-10-18. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27748532-2018-10-15-aebb0330f817`](#source-pubmed-observation-pmid-27748532-2018-10-15-aebb0330f817))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27748532-2018-10-15-aebb0330f817`](#source-pubmed-observation-pmid-27748532-2018-10-15-aebb0330f817))

### Sources

<a id="source-pubmed-observation-pmid-27748532-2018-10-15-aebb0330f817"></a>
- **PubMed record PMID 27748532 · retained source version 1:2018-10-15:current:aebb0330f8176c574ad1e8ce48095b2804a7cbce908e521fd8f822db07a52683** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27748532/) (`pubmed-observation-pmid-27748532-2018-10-15-aebb0330f817`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 27748532." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-27748532-abaloparatide-v1 SHA-256: 545bf3ab9d3e4f2d7b880430de0590d866cecc3adeead5f1bfd8b2733dfa39e2.

---

<a id="pubmed-pmid-27859635-abaloparatide-v1"></a>

## PubMed record PMID 27859635

> PeptideScanner retained PubMed bibliographic metadata for PMID 27859635 at 2026-07-30T20:53:23.986Z. PubMed recorded a metadata revision date of 2019-05-09 and an Entrez history date of 2016-11-19. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-27859635-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-05-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27859635-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-27859635-abaloparatide-v1
- Content SHA-256: `bb73a1dd4f38a76ed8c25e477b0959fb4e5405b2e9384d3a5fdd046d939ddd82`

### Claims and source pins

#### Headline

PubMed record PMID 27859635 ([`pubmed-observation-pmid-27859635-2019-05-09-943903004fdb`](#source-pubmed-observation-pmid-27859635-2019-05-09-943903004fdb))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 27859635 at 2026-07-30T20:53:23.986Z. PubMed recorded a metadata revision date of 2019-05-09 and an Entrez history date of 2016-11-19. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27859635-2019-05-09-943903004fdb`](#source-pubmed-observation-pmid-27859635-2019-05-09-943903004fdb))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 27859635 at 2026-07-30T20:53:23.986Z. PubMed recorded a metadata revision date of 2019-05-09 and an Entrez history date of 2016-11-19. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27859635-2019-05-09-943903004fdb`](#source-pubmed-observation-pmid-27859635-2019-05-09-943903004fdb))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27859635-2019-05-09-943903004fdb`](#source-pubmed-observation-pmid-27859635-2019-05-09-943903004fdb))

### Sources

<a id="source-pubmed-observation-pmid-27859635-2019-05-09-943903004fdb"></a>
- **PubMed record PMID 27859635 · retained source version 1:2019-05-09:current:943903004fdb663734287534627869bd58ac109d2ef7d860e9bbbf63747e7b58** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27859635/) (`pubmed-observation-pmid-27859635-2019-05-09-943903004fdb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 27859635." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-27859635-abaloparatide-v1 SHA-256: bb73a1dd4f38a76ed8c25e477b0959fb4e5405b2e9384d3a5fdd046d939ddd82.

---

<a id="pubmed-pmid-27894941-abaloparatide-v1"></a>

## PubMed record PMID 27894941

> PeptideScanner retained PubMed bibliographic metadata for PMID 27894941 at 2026-07-30T21:22:58.009Z. PubMed recorded a metadata revision date of 2017-12-23 and an Entrez history date of 2016-11-30. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-27894941-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-12-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27894941-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-27894941-abaloparatide-v1
- Content SHA-256: `654a2525af0ce4532cabfc76b31bd310d97d257019a6b099c06b2ad1ec14680d`

### Claims and source pins

#### Headline

PubMed record PMID 27894941 ([`pubmed-observation-pmid-27894941-2017-12-23-3b9a855a4583`](#source-pubmed-observation-pmid-27894941-2017-12-23-3b9a855a4583))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 27894941 at 2026-07-30T21:22:58.009Z. PubMed recorded a metadata revision date of 2017-12-23 and an Entrez history date of 2016-11-30. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27894941-2017-12-23-3b9a855a4583`](#source-pubmed-observation-pmid-27894941-2017-12-23-3b9a855a4583))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 27894941 at 2026-07-30T21:22:58.009Z. PubMed recorded a metadata revision date of 2017-12-23 and an Entrez history date of 2016-11-30. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27894941-2017-12-23-3b9a855a4583`](#source-pubmed-observation-pmid-27894941-2017-12-23-3b9a855a4583))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27894941-2017-12-23-3b9a855a4583`](#source-pubmed-observation-pmid-27894941-2017-12-23-3b9a855a4583))

### Sources

<a id="source-pubmed-observation-pmid-27894941-2017-12-23-3b9a855a4583"></a>
- **PubMed record PMID 27894941 · retained source version 1:2017-12-23:current:3b9a855a4583bd48a1a0cf1f7e94ff6c5db2072df7bac7acb44686006dce3ecb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27894941/) (`pubmed-observation-pmid-27894941-2017-12-23-3b9a855a4583`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 27894941." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-27894941-abaloparatide-v1 SHA-256: 654a2525af0ce4532cabfc76b31bd310d97d257019a6b099c06b2ad1ec14680d.

---

<a id="pubmed-pmid-28160873-abaloparatide-v1"></a>

## PubMed record PMID 28160873

> PeptideScanner retained PubMed bibliographic metadata for PMID 28160873 at 2026-07-30T21:25:18.679Z. PubMed recorded a metadata revision date of 2017-05-31 and an Entrez history date of 2017-02-06. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-28160873-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-05-31
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28160873-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-28160873-abaloparatide-v1
- Content SHA-256: `f07bb1f87707c43f2e52a394395d1a325fad4f9db8169678edc7c0a73262dcd4`

### Claims and source pins

#### Headline

PubMed record PMID 28160873 ([`pubmed-observation-pmid-28160873-2017-05-31-f13d1c149ea3`](#source-pubmed-observation-pmid-28160873-2017-05-31-f13d1c149ea3))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 28160873 at 2026-07-30T21:25:18.679Z. PubMed recorded a metadata revision date of 2017-05-31 and an Entrez history date of 2017-02-06. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-28160873-2017-05-31-f13d1c149ea3`](#source-pubmed-observation-pmid-28160873-2017-05-31-f13d1c149ea3))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 28160873 at 2026-07-30T21:25:18.679Z. PubMed recorded a metadata revision date of 2017-05-31 and an Entrez history date of 2017-02-06. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-28160873-2017-05-31-f13d1c149ea3`](#source-pubmed-observation-pmid-28160873-2017-05-31-f13d1c149ea3))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28160873-2017-05-31-f13d1c149ea3`](#source-pubmed-observation-pmid-28160873-2017-05-31-f13d1c149ea3))

### Sources

<a id="source-pubmed-observation-pmid-28160873-2017-05-31-f13d1c149ea3"></a>
- **PubMed record PMID 28160873 · retained source version 1:2017-05-31:current:f13d1c149ea37fa77521b8877fb013476b70159c1dcefcbbd2bfc3585c579a7b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28160873/) (`pubmed-observation-pmid-28160873-2017-05-31-f13d1c149ea3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 28160873." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-28160873-abaloparatide-v1 SHA-256: f07bb1f87707c43f2e52a394395d1a325fad4f9db8169678edc7c0a73262dcd4.

---

<a id="pubmed-pmid-28389324-abaloparatide-v1"></a>

## PubMed record PMID 28389324

> PeptideScanner retained PubMed bibliographic metadata for PMID 28389324 at 2026-07-30T21:09:25.134Z. PubMed recorded a metadata revision date of 2018-12-02 and an Entrez history date of 2017-04-09. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-28389324-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28389324-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-28389324-abaloparatide-v1
- Content SHA-256: `14fa6ac83abc969f9621cc121c0b9c12b80ae8dabc16dfa1bb621a100d86c5d3`

### Claims and source pins

#### Headline

PubMed record PMID 28389324 ([`pubmed-observation-pmid-28389324-2018-12-02-eff92a3732c9`](#source-pubmed-observation-pmid-28389324-2018-12-02-eff92a3732c9))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 28389324 at 2026-07-30T21:09:25.134Z. PubMed recorded a metadata revision date of 2018-12-02 and an Entrez history date of 2017-04-09. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-28389324-2018-12-02-eff92a3732c9`](#source-pubmed-observation-pmid-28389324-2018-12-02-eff92a3732c9))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 28389324 at 2026-07-30T21:09:25.134Z. PubMed recorded a metadata revision date of 2018-12-02 and an Entrez history date of 2017-04-09. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-28389324-2018-12-02-eff92a3732c9`](#source-pubmed-observation-pmid-28389324-2018-12-02-eff92a3732c9))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28389324-2018-12-02-eff92a3732c9`](#source-pubmed-observation-pmid-28389324-2018-12-02-eff92a3732c9))

### Sources

<a id="source-pubmed-observation-pmid-28389324-2018-12-02-eff92a3732c9"></a>
- **PubMed record PMID 28389324 · retained source version 1:2018-12-02:current:eff92a3732c9e6c8384ca3980cdffa8eccd25a1853007b4a4fb659465b87c500** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28389324/) (`pubmed-observation-pmid-28389324-2018-12-02-eff92a3732c9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 28389324." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-28389324-abaloparatide-v1 SHA-256: 14fa6ac83abc969f9621cc121c0b9c12b80ae8dabc16dfa1bb621a100d86c5d3.

---

<a id="pubmed-pmid-28609423-abaloparatide-v1"></a>

## PubMed record PMID 28609423

> PeptideScanner retained PubMed bibliographic metadata for PMID 28609423 at 2026-07-30T21:09:26.729Z. PubMed recorded a metadata revision date of 2018-11-05 and an Entrez history date of 2017-06-14. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-28609423-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28609423-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-28609423-abaloparatide-v1
- Content SHA-256: `39ee80b9886b59b619d81884f7268ea09395dc7b0ef749d5042430b699b28512`

### Claims and source pins

#### Headline

PubMed record PMID 28609423 ([`pubmed-observation-pmid-28609423-2018-11-05-df73df22ca9c`](#source-pubmed-observation-pmid-28609423-2018-11-05-df73df22ca9c))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 28609423 at 2026-07-30T21:09:26.729Z. PubMed recorded a metadata revision date of 2018-11-05 and an Entrez history date of 2017-06-14. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-28609423-2018-11-05-df73df22ca9c`](#source-pubmed-observation-pmid-28609423-2018-11-05-df73df22ca9c))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 28609423 at 2026-07-30T21:09:26.729Z. PubMed recorded a metadata revision date of 2018-11-05 and an Entrez history date of 2017-06-14. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-28609423-2018-11-05-df73df22ca9c`](#source-pubmed-observation-pmid-28609423-2018-11-05-df73df22ca9c))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28609423-2018-11-05-df73df22ca9c`](#source-pubmed-observation-pmid-28609423-2018-11-05-df73df22ca9c))

### Sources

<a id="source-pubmed-observation-pmid-28609423-2018-11-05-df73df22ca9c"></a>
- **PubMed record PMID 28609423 · retained source version 1:2018-11-05:current:df73df22ca9c89ae082a8c3fa6acde71c259e3b1a56e4d2457a3d9d091baebe8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28609423/) (`pubmed-observation-pmid-28609423-2018-11-05-df73df22ca9c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 28609423." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-28609423-abaloparatide-v1 SHA-256: 39ee80b9886b59b619d81884f7268ea09395dc7b0ef749d5042430b699b28512.

---

<a id="pubmed-pmid-28624872-abaloparatide-v1"></a>

## Abaloparatide: First Global Approval.

> PubMed lists PMID 28624872 in Drugs as Journal Article, with publication-date metadata of 2017-08 (month precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28624872-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28624872-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-28624872-abaloparatide-v1
- Content SHA-256: `8836980ee69f5be233a0904761f92dce6dcb02020a2e97d525828d99ec7fa7f5`

### Claims and source pins

#### Headline

Abaloparatide: First Global Approval. ([`pubmed-observation-pmid-28624872-2026-01-27-176244bcd04a`](#source-pubmed-observation-pmid-28624872-2026-01-27-176244bcd04a))

#### Summary

PubMed lists PMID 28624872 in Drugs as Journal Article, with publication-date metadata of 2017-08 (month precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28624872-2026-01-27-176244bcd04a`](#source-pubmed-observation-pmid-28624872-2026-01-27-176244bcd04a))

#### Paragraph 1

PubMed lists PMID 28624872 in Drugs as Journal Article, with publication-date metadata of 2017-08 (month precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28624872-2026-01-27-176244bcd04a`](#source-pubmed-observation-pmid-28624872-2026-01-27-176244bcd04a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28624872-2026-01-27-176244bcd04a`](#source-pubmed-observation-pmid-28624872-2026-01-27-176244bcd04a))

### Sources

<a id="source-pubmed-observation-pmid-28624872-2026-01-27-176244bcd04a"></a>
- **Abaloparatide: First Global Approval. · retained source version 1:2026-01-27:current:176244bcd04ad856ddcb9708bf3d18b7b4660fb21f55eaff74a921d6e1eaeda7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28624872/) (`pubmed-observation-pmid-28624872-2026-01-27-176244bcd04a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide: First Global Approval." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-28624872-abaloparatide-v1 SHA-256: 8836980ee69f5be233a0904761f92dce6dcb02020a2e97d525828d99ec7fa7f5.

---

<a id="pubmed-pmid-29251010-abaloparatide-v1"></a>

## PubMed record PMID 29251010

> PeptideScanner retained PubMed bibliographic metadata for PMID 29251010 at 2026-07-30T21:09:28.247Z. PubMed recorded a metadata revision date of 2018-12-02 and an Entrez history date of 2017-12-19. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-29251010-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29251010-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-29251010-abaloparatide-v1
- Content SHA-256: `e8176bb98917b916a18e80467a4febf46336466bb3292127cbf17c704f8184fc`

### Claims and source pins

#### Headline

PubMed record PMID 29251010 ([`pubmed-observation-pmid-29251010-2018-12-02-9131fcc30522`](#source-pubmed-observation-pmid-29251010-2018-12-02-9131fcc30522))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 29251010 at 2026-07-30T21:09:28.247Z. PubMed recorded a metadata revision date of 2018-12-02 and an Entrez history date of 2017-12-19. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-29251010-2018-12-02-9131fcc30522`](#source-pubmed-observation-pmid-29251010-2018-12-02-9131fcc30522))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 29251010 at 2026-07-30T21:09:28.247Z. PubMed recorded a metadata revision date of 2018-12-02 and an Entrez history date of 2017-12-19. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-29251010-2018-12-02-9131fcc30522`](#source-pubmed-observation-pmid-29251010-2018-12-02-9131fcc30522))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29251010-2018-12-02-9131fcc30522`](#source-pubmed-observation-pmid-29251010-2018-12-02-9131fcc30522))

### Sources

<a id="source-pubmed-observation-pmid-29251010-2018-12-02-9131fcc30522"></a>
- **PubMed record PMID 29251010 · retained source version 1:2018-12-02:current:9131fcc305226714dae4ffd962f752d673b0c7bbfad51f9b926a46b2b75fc74f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29251010/) (`pubmed-observation-pmid-29251010-2018-12-02-9131fcc30522`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 29251010." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-29251010-abaloparatide-v1 SHA-256: e8176bb98917b916a18e80467a4febf46336466bb3292127cbf17c704f8184fc.

---

<a id="pubmed-pmid-29260289-abaloparatide-v1"></a>

## PubMed record PMID 29260289

> PeptideScanner retained PubMed bibliographic metadata for PMID 29260289 at 2026-07-30T20:57:06.138Z. PubMed recorded a metadata revision date of 2019-02-25 and an Entrez history date of 2017-12-21. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-29260289-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-02-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29260289-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-29260289-abaloparatide-v1
- Content SHA-256: `eb766d8abbd9c24dc2945dd0a46846a09938d515127d5be4ee9c7186b3896caa`

### Claims and source pins

#### Headline

PubMed record PMID 29260289 ([`pubmed-observation-pmid-29260289-2019-02-25-e15f996dfaa7`](#source-pubmed-observation-pmid-29260289-2019-02-25-e15f996dfaa7))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 29260289 at 2026-07-30T20:57:06.138Z. PubMed recorded a metadata revision date of 2019-02-25 and an Entrez history date of 2017-12-21. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-29260289-2019-02-25-e15f996dfaa7`](#source-pubmed-observation-pmid-29260289-2019-02-25-e15f996dfaa7))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 29260289 at 2026-07-30T20:57:06.138Z. PubMed recorded a metadata revision date of 2019-02-25 and an Entrez history date of 2017-12-21. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-29260289-2019-02-25-e15f996dfaa7`](#source-pubmed-observation-pmid-29260289-2019-02-25-e15f996dfaa7))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29260289-2019-02-25-e15f996dfaa7`](#source-pubmed-observation-pmid-29260289-2019-02-25-e15f996dfaa7))

### Sources

<a id="source-pubmed-observation-pmid-29260289-2019-02-25-e15f996dfaa7"></a>
- **PubMed record PMID 29260289 · retained source version 1:2019-02-25:current:e15f996dfaa70bec31f7538732a4aa708d62ae47b1bd1082a2264ae0b547eff8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29260289/) (`pubmed-observation-pmid-29260289-2019-02-25-e15f996dfaa7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 29260289." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-29260289-abaloparatide-v1 SHA-256: eb766d8abbd9c24dc2945dd0a46846a09938d515127d5be4ee9c7186b3896caa.

---

<a id="pubmed-pmid-29800372-abaloparatide-v1"></a>

## PubMed record PMID 29800372

> PeptideScanner retained PubMed bibliographic metadata for PMID 29800372 at 2026-07-30T20:55:52.341Z. PubMed recorded a metadata revision date of 2019-03-26 and an Entrez history date of 2018-05-26. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-29800372-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-03-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29800372-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-29800372-abaloparatide-v1
- Content SHA-256: `77261da87c61e854956dffdbd8e245ec46159dff742f3be486ecf5838c85c6f9`

### Claims and source pins

#### Headline

PubMed record PMID 29800372 ([`pubmed-observation-pmid-29800372-2019-03-26-63fe3648ae02`](#source-pubmed-observation-pmid-29800372-2019-03-26-63fe3648ae02))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 29800372 at 2026-07-30T20:55:52.341Z. PubMed recorded a metadata revision date of 2019-03-26 and an Entrez history date of 2018-05-26. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-29800372-2019-03-26-63fe3648ae02`](#source-pubmed-observation-pmid-29800372-2019-03-26-63fe3648ae02))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 29800372 at 2026-07-30T20:55:52.341Z. PubMed recorded a metadata revision date of 2019-03-26 and an Entrez history date of 2018-05-26. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-29800372-2019-03-26-63fe3648ae02`](#source-pubmed-observation-pmid-29800372-2019-03-26-63fe3648ae02))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29800372-2019-03-26-63fe3648ae02`](#source-pubmed-observation-pmid-29800372-2019-03-26-63fe3648ae02))

### Sources

<a id="source-pubmed-observation-pmid-29800372-2019-03-26-63fe3648ae02"></a>
- **PubMed record PMID 29800372 · retained source version 1:2019-03-26:current:63fe3648ae020853b832f62085ebc73fc7835d8516ec9f645a80afed71e1e8d0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29800372/) (`pubmed-observation-pmid-29800372-2019-03-26-63fe3648ae02`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 29800372." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-29800372-abaloparatide-v1 SHA-256: 77261da87c61e854956dffdbd8e245ec46159dff742f3be486ecf5838c85c6f9.

---

<a id="pubmed-pmid-29911694-abaloparatide-v1"></a>

## PubMed record PMID 29911694

> PeptideScanner retained PubMed bibliographic metadata for PMID 29911694 at 2026-07-30T21:10:57.556Z. PubMed recorded a metadata revision date of 2018-08-23 and an Entrez history date of 2018-06-19. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-29911694-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-08-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29911694-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-29911694-abaloparatide-v1
- Content SHA-256: `b05a006e56ced0d2404d848e6eaa6b8e149d848f68188f38eb9bae078e28f725`

### Claims and source pins

#### Headline

PubMed record PMID 29911694 ([`pubmed-observation-pmid-29911694-2018-08-23-4502810d9f62`](#source-pubmed-observation-pmid-29911694-2018-08-23-4502810d9f62))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 29911694 at 2026-07-30T21:10:57.556Z. PubMed recorded a metadata revision date of 2018-08-23 and an Entrez history date of 2018-06-19. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-29911694-2018-08-23-4502810d9f62`](#source-pubmed-observation-pmid-29911694-2018-08-23-4502810d9f62))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 29911694 at 2026-07-30T21:10:57.556Z. PubMed recorded a metadata revision date of 2018-08-23 and an Entrez history date of 2018-06-19. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-29911694-2018-08-23-4502810d9f62`](#source-pubmed-observation-pmid-29911694-2018-08-23-4502810d9f62))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29911694-2018-08-23-4502810d9f62`](#source-pubmed-observation-pmid-29911694-2018-08-23-4502810d9f62))

### Sources

<a id="source-pubmed-observation-pmid-29911694-2018-08-23-4502810d9f62"></a>
- **PubMed record PMID 29911694 · retained source version 1:2018-08-23:current:4502810d9f62222a0efe0bb14fa28dacea35273b20c782e8f3be45b94331e2fa** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29911694/) (`pubmed-observation-pmid-29911694-2018-08-23-4502810d9f62`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 29911694." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-29911694-abaloparatide-v1 SHA-256: b05a006e56ced0d2404d848e6eaa6b8e149d848f68188f38eb9bae078e28f725.

---

<a id="pubmed-pmid-32665529-abaloparatide-v1"></a>

## Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend.

> PubMed lists PMID 32665529 in Menopause (New York, N.Y.) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-10 (month precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32665529-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-06-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32665529-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-32665529-abaloparatide-v1
- Content SHA-256: `2e2a869a50fc7f00a758ffba48edd1cf188b14e00daa07d79f8ea5781c388bb4`

### Claims and source pins

#### Headline

Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend. ([`pubmed-observation-pmid-32665529-2021-06-02-e43372307349`](#source-pubmed-observation-pmid-32665529-2021-06-02-e43372307349))

#### Summary

PubMed lists PMID 32665529 in Menopause (New York, N.Y.) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-10 (month precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32665529-2021-06-02-e43372307349`](#source-pubmed-observation-pmid-32665529-2021-06-02-e43372307349))

#### Paragraph 1

PubMed lists PMID 32665529 in Menopause (New York, N.Y.) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-10 (month precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32665529-2021-06-02-e43372307349`](#source-pubmed-observation-pmid-32665529-2021-06-02-e43372307349))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32665529-2021-06-02-e43372307349`](#source-pubmed-observation-pmid-32665529-2021-06-02-e43372307349))

### Sources

<a id="source-pubmed-observation-pmid-32665529-2021-06-02-e43372307349"></a>
- **Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend. · retained source version 1:2021-06-02:current:e4337230734991453b318d7c5bbf1b1ebfb2976b469500c37a00c78355a67f78** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32665529/) (`pubmed-observation-pmid-32665529-2021-06-02-e43372307349`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-32665529-abaloparatide-v1 SHA-256: 2e2a869a50fc7f00a758ffba48edd1cf188b14e00daa07d79f8ea5781c388bb4.

---

<a id="pubmed-pmid-33615100-abaloparatide-v1"></a>

## Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study.

> PubMed lists PMID 33615100 in JBMR plus as Published Erratum, with publication-date metadata of 2020-11-03 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33615100-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-02-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33615100-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-33615100-abaloparatide-v1
- Content SHA-256: `95ca27fcc23d405a89e7cf3cb92679666359ccd06c85a1768eff89fa855a8860`

### Claims and source pins

#### Headline

Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study. ([`pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac`](#source-pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac))

#### Summary

PubMed lists PMID 33615100 in JBMR plus as Published Erratum, with publication-date metadata of 2020-11-03 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac`](#source-pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac))

#### Paragraph 1

PubMed lists PMID 33615100 in JBMR plus as Published Erratum, with publication-date metadata of 2020-11-03 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac`](#source-pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac`](#source-pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac))

### Sources

<a id="source-pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac"></a>
- **Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study. · retained source version 1:2021-02-23:current:5e4e601601ac9c46349bf3a26bf1f6e02bd15b3465ecec853a73edc7521e816a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33615100/) (`pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-33615100-abaloparatide-v1 SHA-256: 95ca27fcc23d405a89e7cf3cb92679666359ccd06c85a1768eff89fa855a8860.

---

<a id="pubmed-pmid-33638863-abaloparatide-v1"></a>

## Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.

> PubMed lists PMID 33638863 in Clinical drug investigation as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2021-02-27 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33638863-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-03-31
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33638863-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-33638863-abaloparatide-v1
- Content SHA-256: `c46afa87d4551a7e73e2bdff7de80c0bd6ec9c73043805f271b485d055dbd300`

### Claims and source pins

#### Headline

Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density. ([`pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e`](#source-pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e))

#### Summary

PubMed lists PMID 33638863 in Clinical drug investigation as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2021-02-27 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e`](#source-pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e))

#### Paragraph 1

PubMed lists PMID 33638863 in Clinical drug investigation as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2021-02-27 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e`](#source-pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e`](#source-pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e))

### Sources

<a id="source-pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e"></a>
- **Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density. · retained source version 1:2024-03-31:current:7d0404213a0e8fa90c0adc92e9249edc2eae1da988a7357d53aeffa63c7c4166** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33638863/) (`pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-33638863-abaloparatide-v1 SHA-256: c46afa87d4551a7e73e2bdff7de80c0bd6ec9c73043805f271b485d055dbd300.

---

<a id="pubmed-pmid-33778325-abaloparatide-v1"></a>

## Abaloparatide Real-World Patient Experience Study.

> PubMed lists PMID 33778325 in JBMR plus as Journal Article, with publication-date metadata of 2021-02-04 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33778325-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-03-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33778325-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-33778325-abaloparatide-v1
- Content SHA-256: `68f0539fa19bf137a4c590af3b0f5b45ec248a8cc4298eefad9d2ab6abac193c`

### Claims and source pins

#### Headline

Abaloparatide Real-World Patient Experience Study. ([`pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e`](#source-pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e))

#### Summary

PubMed lists PMID 33778325 in JBMR plus as Journal Article, with publication-date metadata of 2021-02-04 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e`](#source-pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e))

#### Paragraph 1

PubMed lists PMID 33778325 in JBMR plus as Journal Article, with publication-date metadata of 2021-02-04 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e`](#source-pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e`](#source-pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e))

### Sources

<a id="source-pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e"></a>
- **Abaloparatide Real-World Patient Experience Study. · retained source version 1:2021-03-30:current:951f8ae1283eff3af0ca47104ad81ab12cf661211168394edc09d1a2de7504cf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33778325/) (`pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abaloparatide Real-World Patient Experience Study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-33778325-abaloparatide-v1 SHA-256: 68f0539fa19bf137a4c590af3b0f5b45ec248a8cc4298eefad9d2ab6abac193c.

---

<a id="pubmed-pmid-34786439-abaloparatide-v1"></a>

## The use of abaloparatide to treat nonunion following dorsal closing wedge osteotomy for Freiberg's disease: A case report.

> PubMed lists PMID 34786439 in Bone reports as Case Reports, Journal Article, with publication-date metadata of 2021-10-30 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34786439-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-11-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34786439-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-34786439-abaloparatide-v1
- Content SHA-256: `d2ac2c42731d59a75a4fed6ca7a57a88ef72622d5316cfbdf8037e9d67f953e8`

### Claims and source pins

#### Headline

The use of abaloparatide to treat nonunion following dorsal closing wedge osteotomy for Freiberg's disease: A case report. ([`pubmed-observation-pmid-34786439-2021-11-18-8cb15da888f6`](#source-pubmed-observation-pmid-34786439-2021-11-18-8cb15da888f6))

#### Summary

PubMed lists PMID 34786439 in Bone reports as Case Reports, Journal Article, with publication-date metadata of 2021-10-30 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34786439-2021-11-18-8cb15da888f6`](#source-pubmed-observation-pmid-34786439-2021-11-18-8cb15da888f6))

#### Paragraph 1

PubMed lists PMID 34786439 in Bone reports as Case Reports, Journal Article, with publication-date metadata of 2021-10-30 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34786439-2021-11-18-8cb15da888f6`](#source-pubmed-observation-pmid-34786439-2021-11-18-8cb15da888f6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34786439-2021-11-18-8cb15da888f6`](#source-pubmed-observation-pmid-34786439-2021-11-18-8cb15da888f6))

### Sources

<a id="source-pubmed-observation-pmid-34786439-2021-11-18-8cb15da888f6"></a>
- **The use of abaloparatide to treat nonunion following dorsal closing wedge osteotomy for Freiberg's disease: A case report. · retained source version 1:2021-11-18:current:8cb15da888f6aa7693e4b4d7b4ce171812f325e0cde82bea8d9d71ec1c87cce9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34786439/) (`pubmed-observation-pmid-34786439-2021-11-18-8cb15da888f6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The use of abaloparatide to treat nonunion following dorsal closing wedge osteotomy for Freiberg's disease: A case report." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-34786439-abaloparatide-v1 SHA-256: d2ac2c42731d59a75a4fed6ca7a57a88ef72622d5316cfbdf8037e9d67f953e8.

---

<a id="pubmed-pmid-38350110-abaloparatide-v1"></a>

## Biodegradable Nanoflowers with Abaloparatide Spatiotemporal Management of Functional Alveolar Bone Regeneration.

> PubMed lists PMID 38350110 in Nano letters as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-02-13 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38350110-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38350110-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-38350110-abaloparatide-v1
- Content SHA-256: `15296caebb43abf21b53f0b693dd35a913887a59004bf11a3ad259df71cbbb42`

### Claims and source pins

#### Headline

Biodegradable Nanoflowers with Abaloparatide Spatiotemporal Management of Functional Alveolar Bone Regeneration. ([`pubmed-observation-pmid-38350110-2025-07-29-2edc72b2026e`](#source-pubmed-observation-pmid-38350110-2025-07-29-2edc72b2026e))

#### Summary

PubMed lists PMID 38350110 in Nano letters as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-02-13 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38350110-2025-07-29-2edc72b2026e`](#source-pubmed-observation-pmid-38350110-2025-07-29-2edc72b2026e))

#### Paragraph 1

PubMed lists PMID 38350110 in Nano letters as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-02-13 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38350110-2025-07-29-2edc72b2026e`](#source-pubmed-observation-pmid-38350110-2025-07-29-2edc72b2026e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38350110-2025-07-29-2edc72b2026e`](#source-pubmed-observation-pmid-38350110-2025-07-29-2edc72b2026e))

### Sources

<a id="source-pubmed-observation-pmid-38350110-2025-07-29-2edc72b2026e"></a>
- **Biodegradable Nanoflowers with Abaloparatide Spatiotemporal Management of Functional Alveolar Bone Regeneration. · retained source version 1:2025-07-29:current:2edc72b2026ed913d8d730ee0dc4d71577c6aa187a3361e57bea8a9c912e158c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38350110/) (`pubmed-observation-pmid-38350110-2025-07-29-2edc72b2026e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Biodegradable Nanoflowers with Abaloparatide Spatiotemporal Management of Functional Alveolar Bone Regeneration." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-38350110-abaloparatide-v1 SHA-256: 15296caebb43abf21b53f0b693dd35a913887a59004bf11a3ad259df71cbbb42.

---

<a id="pubmed-pmid-39789749-abaloparatide-v1"></a>

## PubMed record PMID 39789749

> PeptideScanner retained PubMed bibliographic metadata for PMID 39789749 at 2026-08-10T18:13:36.068Z. PubMed recorded a metadata revision date of 2026-07-07 and an Entrez history date of 2025-01-10. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-39789749-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-07
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39789749-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-39789749-abaloparatide-v1
- Content SHA-256: `edd3020c173110e98c201adc212ec4a3e3949fa061a2c6a36fe23ac063638691`

### Claims and source pins

#### Headline

PubMed record PMID 39789749 ([`pubmed-observation-pmid-39789749-2026-07-07-c98bcbbbe8d4`](#source-pubmed-observation-pmid-39789749-2026-07-07-c98bcbbbe8d4))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 39789749 at 2026-08-10T18:13:36.068Z. PubMed recorded a metadata revision date of 2026-07-07 and an Entrez history date of 2025-01-10. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39789749-2026-07-07-c98bcbbbe8d4`](#source-pubmed-observation-pmid-39789749-2026-07-07-c98bcbbbe8d4))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 39789749 at 2026-08-10T18:13:36.068Z. PubMed recorded a metadata revision date of 2026-07-07 and an Entrez history date of 2025-01-10. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39789749-2026-07-07-c98bcbbbe8d4`](#source-pubmed-observation-pmid-39789749-2026-07-07-c98bcbbbe8d4))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39789749-2026-07-07-c98bcbbbe8d4`](#source-pubmed-observation-pmid-39789749-2026-07-07-c98bcbbbe8d4))

### Sources

<a id="source-pubmed-observation-pmid-39789749-2026-07-07-c98bcbbbe8d4"></a>
- **PubMed record PMID 39789749 · retained source version 1:2026-07-07:current:c98bcbbbe8d4e871e879dfb6a0b8297b7e97e31fd8ae82251ad069c9195d8472** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39789749/) (`pubmed-observation-pmid-39789749-2026-07-07-c98bcbbbe8d4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 39789749." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-39789749-abaloparatide-v1 SHA-256: edd3020c173110e98c201adc212ec4a3e3949fa061a2c6a36fe23ac063638691.

---

<a id="pubmed-pmid-40588314-abaloparatide-v1"></a>

## ▼Abaloparatide (Eladynos) for osteoporosis.

> PubMed lists PMID 40588314 in Drug and therapeutics bulletin as Journal Article, with publication-date metadata of 2025-06-30 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40588314-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-09-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40588314-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-40588314-abaloparatide-v1
- Content SHA-256: `7cd3fa5791588995058f81ace186cc909af0561a6cfdc00310759d1875288279`

### Claims and source pins

#### Headline

▼Abaloparatide (Eladynos) for osteoporosis. ([`pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce`](#source-pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce))

#### Summary

PubMed lists PMID 40588314 in Drug and therapeutics bulletin as Journal Article, with publication-date metadata of 2025-06-30 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce`](#source-pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce))

#### Paragraph 1

PubMed lists PMID 40588314 in Drug and therapeutics bulletin as Journal Article, with publication-date metadata of 2025-06-30 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce`](#source-pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce`](#source-pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce))

### Sources

<a id="source-pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce"></a>
- **▼Abaloparatide (Eladynos) for osteoporosis. · retained source version 1:2025-09-11:current:9a8831c827ce9a09c441fc4c5892c437f6a3e79f7208e6fc1e0a41aeb9bc83eb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40588314/) (`pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "▼Abaloparatide (Eladynos) for osteoporosis." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-40588314-abaloparatide-v1 SHA-256: 7cd3fa5791588995058f81ace186cc909af0561a6cfdc00310759d1875288279.

---

<a id="pubmed-pmid-40890141-abaloparatide-v1"></a>

## PubMed record PMID 40890141

> PeptideScanner retained PubMed bibliographic metadata for PMID 40890141 at 2026-07-30T16:14:11.108Z. PubMed recorded a metadata revision date of 2026-06-19 and an Entrez history date of 2025-09-01. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-40890141-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40890141-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-40890141-abaloparatide-v1
- Content SHA-256: `842b75ee76a7d811ce3ea729abd214d503969de8469c3d46c5385cef508b090b`

### Claims and source pins

#### Headline

PubMed record PMID 40890141 ([`pubmed-observation-pmid-40890141-2026-06-19-56e4fae8c38a`](#source-pubmed-observation-pmid-40890141-2026-06-19-56e4fae8c38a))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 40890141 at 2026-07-30T16:14:11.108Z. PubMed recorded a metadata revision date of 2026-06-19 and an Entrez history date of 2025-09-01. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40890141-2026-06-19-56e4fae8c38a`](#source-pubmed-observation-pmid-40890141-2026-06-19-56e4fae8c38a))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 40890141 at 2026-07-30T16:14:11.108Z. PubMed recorded a metadata revision date of 2026-06-19 and an Entrez history date of 2025-09-01. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40890141-2026-06-19-56e4fae8c38a`](#source-pubmed-observation-pmid-40890141-2026-06-19-56e4fae8c38a))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40890141-2026-06-19-56e4fae8c38a`](#source-pubmed-observation-pmid-40890141-2026-06-19-56e4fae8c38a))

### Sources

<a id="source-pubmed-observation-pmid-40890141-2026-06-19-56e4fae8c38a"></a>
- **PubMed record PMID 40890141 · retained source version 1:2026-06-19:current:56e4fae8c38a4e5d6ade225bd75489dafe01bff891c107c15ef99f982fc850f7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40890141/) (`pubmed-observation-pmid-40890141-2026-06-19-56e4fae8c38a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 40890141." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-40890141-abaloparatide-v1 SHA-256: 842b75ee76a7d811ce3ea729abd214d503969de8469c3d46c5385cef508b090b.

---

<a id="pubmed-pmid-41023931-abaloparatide-v1"></a>

## PubMed record PMID 41023931

> PeptideScanner retained PubMed bibliographic metadata for PMID 41023931 at 2026-07-30T16:14:12.886Z. PubMed recorded a metadata revision date of 2026-06-26 and an Entrez history date of 2025-09-30. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41023931-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41023931-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-41023931-abaloparatide-v1
- Content SHA-256: `ad6753a63bdec2706ec18c712d071224ace92a79fe1a7c53b9302c21776d26e1`

### Claims and source pins

#### Headline

PubMed record PMID 41023931 ([`pubmed-observation-pmid-41023931-2026-06-26-9b3f051e3fe8`](#source-pubmed-observation-pmid-41023931-2026-06-26-9b3f051e3fe8))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41023931 at 2026-07-30T16:14:12.886Z. PubMed recorded a metadata revision date of 2026-06-26 and an Entrez history date of 2025-09-30. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41023931-2026-06-26-9b3f051e3fe8`](#source-pubmed-observation-pmid-41023931-2026-06-26-9b3f051e3fe8))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41023931 at 2026-07-30T16:14:12.886Z. PubMed recorded a metadata revision date of 2026-06-26 and an Entrez history date of 2025-09-30. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41023931-2026-06-26-9b3f051e3fe8`](#source-pubmed-observation-pmid-41023931-2026-06-26-9b3f051e3fe8))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41023931-2026-06-26-9b3f051e3fe8`](#source-pubmed-observation-pmid-41023931-2026-06-26-9b3f051e3fe8))

### Sources

<a id="source-pubmed-observation-pmid-41023931-2026-06-26-9b3f051e3fe8"></a>
- **PubMed record PMID 41023931 · retained source version 1:2026-06-26:current:9b3f051e3fe8458d997d2d23e5d7c291ae1835668c74595d67a930c8bc94d406** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41023931/) (`pubmed-observation-pmid-41023931-2026-06-26-9b3f051e3fe8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41023931." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-41023931-abaloparatide-v1 SHA-256: ad6753a63bdec2706ec18c712d071224ace92a79fe1a7c53b9302c21776d26e1.

---

<a id="pubmed-pmid-41506099-abaloparatide-v1"></a>

## PubMed record PMID 41506099

> PeptideScanner retained PubMed bibliographic metadata for PMID 41506099 at 2026-07-30T16:14:13.082Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2026-01-08. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41506099-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41506099-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-41506099-abaloparatide-v1
- Content SHA-256: `5bf7e7dc5db5cecf52bf41b50fd86051d3369d1bc1b338321d9104ca743689fd`

### Claims and source pins

#### Headline

PubMed record PMID 41506099 ([`pubmed-observation-pmid-41506099-2026-06-25-bbd2f6fbe969`](#source-pubmed-observation-pmid-41506099-2026-06-25-bbd2f6fbe969))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41506099 at 2026-07-30T16:14:13.082Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2026-01-08. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41506099-2026-06-25-bbd2f6fbe969`](#source-pubmed-observation-pmid-41506099-2026-06-25-bbd2f6fbe969))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41506099 at 2026-07-30T16:14:13.082Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2026-01-08. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41506099-2026-06-25-bbd2f6fbe969`](#source-pubmed-observation-pmid-41506099-2026-06-25-bbd2f6fbe969))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41506099-2026-06-25-bbd2f6fbe969`](#source-pubmed-observation-pmid-41506099-2026-06-25-bbd2f6fbe969))

### Sources

<a id="source-pubmed-observation-pmid-41506099-2026-06-25-bbd2f6fbe969"></a>
- **PubMed record PMID 41506099 · retained source version 1:2026-06-25:current:bbd2f6fbe96905556c8207ca3220190b1aadd8c5e5bd9ee7fc43a69eec42f918** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41506099/) (`pubmed-observation-pmid-41506099-2026-06-25-bbd2f6fbe969`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41506099." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-41506099-abaloparatide-v1 SHA-256: 5bf7e7dc5db5cecf52bf41b50fd86051d3369d1bc1b338321d9104ca743689fd.

---

<a id="pubmed-pmid-41579168-abaloparatide-v1"></a>

## PubMed record PMID 41579168

> PeptideScanner retained PubMed bibliographic metadata for PMID 41579168 at 2026-07-30T16:11:44.866Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-01-24. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41579168-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41579168-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-41579168-abaloparatide-v1
- Content SHA-256: `7da84c3354e7ef82b6c15d2aa4feef84bd489377f4d61e6e45dc6aa7b93e9aca`

### Claims and source pins

#### Headline

PubMed record PMID 41579168 ([`pubmed-observation-pmid-41579168-2026-07-01-1f33f48183bf`](#source-pubmed-observation-pmid-41579168-2026-07-01-1f33f48183bf))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41579168 at 2026-07-30T16:11:44.866Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-01-24. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41579168-2026-07-01-1f33f48183bf`](#source-pubmed-observation-pmid-41579168-2026-07-01-1f33f48183bf))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41579168 at 2026-07-30T16:11:44.866Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-01-24. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41579168-2026-07-01-1f33f48183bf`](#source-pubmed-observation-pmid-41579168-2026-07-01-1f33f48183bf))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41579168-2026-07-01-1f33f48183bf`](#source-pubmed-observation-pmid-41579168-2026-07-01-1f33f48183bf))

### Sources

<a id="source-pubmed-observation-pmid-41579168-2026-07-01-1f33f48183bf"></a>
- **PubMed record PMID 41579168 · retained source version 1:2026-07-01:current:1f33f48183bfd50fbea083d51eef8073606fb2fea8a936a7077cdced41eab351** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41579168/) (`pubmed-observation-pmid-41579168-2026-07-01-1f33f48183bf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41579168." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-41579168-abaloparatide-v1 SHA-256: 7da84c3354e7ef82b6c15d2aa4feef84bd489377f4d61e6e45dc6aa7b93e9aca.

---

<a id="pubmed-pmid-41714054-abaloparatide-v1"></a>

## PubMed record PMID 41714054

> PeptideScanner retained PubMed bibliographic metadata for PMID 41714054 at 2026-08-10T18:13:42.699Z. PubMed recorded a metadata revision date of 2026-07-08 and an Entrez history date of 2026-02-19. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41714054-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-08
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41714054-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-41714054-abaloparatide-v1
- Content SHA-256: `9f3e7ef100fe1f1d3c1d1912db9f41249830b55e1452ed33fd7ad6a291ef43c3`

### Claims and source pins

#### Headline

PubMed record PMID 41714054 ([`pubmed-observation-pmid-41714054-2026-07-08-af0d9559fa4a`](#source-pubmed-observation-pmid-41714054-2026-07-08-af0d9559fa4a))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41714054 at 2026-08-10T18:13:42.699Z. PubMed recorded a metadata revision date of 2026-07-08 and an Entrez history date of 2026-02-19. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41714054-2026-07-08-af0d9559fa4a`](#source-pubmed-observation-pmid-41714054-2026-07-08-af0d9559fa4a))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41714054 at 2026-08-10T18:13:42.699Z. PubMed recorded a metadata revision date of 2026-07-08 and an Entrez history date of 2026-02-19. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41714054-2026-07-08-af0d9559fa4a`](#source-pubmed-observation-pmid-41714054-2026-07-08-af0d9559fa4a))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41714054-2026-07-08-af0d9559fa4a`](#source-pubmed-observation-pmid-41714054-2026-07-08-af0d9559fa4a))

### Sources

<a id="source-pubmed-observation-pmid-41714054-2026-07-08-af0d9559fa4a"></a>
- **PubMed record PMID 41714054 · retained source version 1:2026-07-08:current:af0d9559fa4afb5f1f89f373242a2996011d6a874ed32a8c05c440468ecb0329** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41714054/) (`pubmed-observation-pmid-41714054-2026-07-08-af0d9559fa4a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41714054." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-41714054-abaloparatide-v1 SHA-256: 9f3e7ef100fe1f1d3c1d1912db9f41249830b55e1452ed33fd7ad6a291ef43c3.

---

<a id="pubmed-pmid-41798079-abaloparatide-v1"></a>

## PubMed record PMID 41798079

> PeptideScanner retained PubMed bibliographic metadata for PMID 41798079 at 2026-07-30T16:23:41.290Z. PubMed recorded a metadata revision date of 2026-03-09 and an Entrez history date of 2026-03-09. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41798079-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-03-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41798079-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-41798079-abaloparatide-v1
- Content SHA-256: `9b63e099c5e7e519faff056050e7ededf68f2b6b07454e88d014a5d77e6b3d49`

### Claims and source pins

#### Headline

PubMed record PMID 41798079 ([`pubmed-observation-pmid-41798079-2026-03-09-fd5aba3c642d`](#source-pubmed-observation-pmid-41798079-2026-03-09-fd5aba3c642d))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41798079 at 2026-07-30T16:23:41.290Z. PubMed recorded a metadata revision date of 2026-03-09 and an Entrez history date of 2026-03-09. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41798079-2026-03-09-fd5aba3c642d`](#source-pubmed-observation-pmid-41798079-2026-03-09-fd5aba3c642d))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41798079 at 2026-07-30T16:23:41.290Z. PubMed recorded a metadata revision date of 2026-03-09 and an Entrez history date of 2026-03-09. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41798079-2026-03-09-fd5aba3c642d`](#source-pubmed-observation-pmid-41798079-2026-03-09-fd5aba3c642d))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41798079-2026-03-09-fd5aba3c642d`](#source-pubmed-observation-pmid-41798079-2026-03-09-fd5aba3c642d))

### Sources

<a id="source-pubmed-observation-pmid-41798079-2026-03-09-fd5aba3c642d"></a>
- **PubMed record PMID 41798079 · retained source version 1:2026-03-09:current:fd5aba3c642d1fe1a5c1f410a7b99b222c07f8a7fd4cccec1b6d5e177a70d549** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41798079/) (`pubmed-observation-pmid-41798079-2026-03-09-fd5aba3c642d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41798079." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-41798079-abaloparatide-v1 SHA-256: 9b63e099c5e7e519faff056050e7ededf68f2b6b07454e88d014a5d77e6b3d49.

---

<a id="pubmed-pmid-41812602-abaloparatide-v1"></a>

## PubMed record PMID 41812602

> PeptideScanner retained PubMed bibliographic metadata for PMID 41812602 at 2026-08-10T10:49:08.791Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-03-11. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41812602-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41812602-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-41812602-abaloparatide-v1
- Content SHA-256: `17c681d277afedc6a7c95edb812a5a33d0b99f581b1b036d0f165c4f4076d196`

### Claims and source pins

#### Headline

PubMed record PMID 41812602 ([`pubmed-observation-pmid-41812602-2026-08-03-2acff690ded5`](#source-pubmed-observation-pmid-41812602-2026-08-03-2acff690ded5))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41812602 at 2026-08-10T10:49:08.791Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-03-11. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41812602-2026-08-03-2acff690ded5`](#source-pubmed-observation-pmid-41812602-2026-08-03-2acff690ded5))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41812602 at 2026-08-10T10:49:08.791Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-03-11. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41812602-2026-08-03-2acff690ded5`](#source-pubmed-observation-pmid-41812602-2026-08-03-2acff690ded5))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41812602-2026-08-03-2acff690ded5`](#source-pubmed-observation-pmid-41812602-2026-08-03-2acff690ded5))

### Sources

<a id="source-pubmed-observation-pmid-41812602-2026-08-03-2acff690ded5"></a>
- **PubMed record PMID 41812602 · retained source version 1:2026-08-03:current:2acff690ded53c2e43dd4a0cd96bcebdc810ccdb85da2a2e80a140671b377b89** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41812602/) (`pubmed-observation-pmid-41812602-2026-08-03-2acff690ded5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41812602." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-41812602-abaloparatide-v1 SHA-256: 17c681d277afedc6a7c95edb812a5a33d0b99f581b1b036d0f165c4f4076d196.

---

<a id="pubmed-pmid-42033613-abaloparatide-v1"></a>

## PubMed record PMID 42033613

> PeptideScanner retained PubMed bibliographic metadata for PMID 42033613 at 2026-07-30T16:14:16.695Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2026-04-25. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42033613-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42033613-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-42033613-abaloparatide-v1
- Content SHA-256: `b3f9f6fd3c93b6f8721c30800d3fc756c51eb4b6d874222c472d548def415ae6`

### Claims and source pins

#### Headline

PubMed record PMID 42033613 ([`pubmed-observation-pmid-42033613-2026-06-27-62e070371cce`](#source-pubmed-observation-pmid-42033613-2026-06-27-62e070371cce))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42033613 at 2026-07-30T16:14:16.695Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2026-04-25. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42033613-2026-06-27-62e070371cce`](#source-pubmed-observation-pmid-42033613-2026-06-27-62e070371cce))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42033613 at 2026-07-30T16:14:16.695Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2026-04-25. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42033613-2026-06-27-62e070371cce`](#source-pubmed-observation-pmid-42033613-2026-06-27-62e070371cce))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42033613-2026-06-27-62e070371cce`](#source-pubmed-observation-pmid-42033613-2026-06-27-62e070371cce))

### Sources

<a id="source-pubmed-observation-pmid-42033613-2026-06-27-62e070371cce"></a>
- **PubMed record PMID 42033613 · retained source version 1:2026-06-27:current:62e070371cce21061928d4fbba8d7f49bf8a38eb55a5ee1198dce34dd77442b4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42033613/) (`pubmed-observation-pmid-42033613-2026-06-27-62e070371cce`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42033613." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-42033613-abaloparatide-v1 SHA-256: b3f9f6fd3c93b6f8721c30800d3fc756c51eb4b6d874222c472d548def415ae6.

---

<a id="pubmed-pmid-42351259-abaloparatide-v1"></a>

## PubMed record PMID 42351259

> PeptideScanner retained PubMed bibliographic metadata for PMID 42351259 at 2026-08-10T18:13:52.323Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42351259-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42351259-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-42351259-abaloparatide-v1
- Content SHA-256: `29cac77d23a9f395ccb348c6612696a62bfd479d8b43d87193a85d75c6552663`

### Claims and source pins

#### Headline

PubMed record PMID 42351259 ([`pubmed-observation-pmid-42351259-2026-07-26-e15d4ad6fca4`](#source-pubmed-observation-pmid-42351259-2026-07-26-e15d4ad6fca4))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42351259 at 2026-08-10T18:13:52.323Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42351259-2026-07-26-e15d4ad6fca4`](#source-pubmed-observation-pmid-42351259-2026-07-26-e15d4ad6fca4))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42351259 at 2026-08-10T18:13:52.323Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42351259-2026-07-26-e15d4ad6fca4`](#source-pubmed-observation-pmid-42351259-2026-07-26-e15d4ad6fca4))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42351259-2026-07-26-e15d4ad6fca4`](#source-pubmed-observation-pmid-42351259-2026-07-26-e15d4ad6fca4))

### Sources

<a id="source-pubmed-observation-pmid-42351259-2026-07-26-e15d4ad6fca4"></a>
- **PubMed record PMID 42351259 · retained source version 1:2026-07-26:current:e15d4ad6fca406cf834f1139f323445a766bd3b81c51cb88cda26fa969de8d55** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42351259/) (`pubmed-observation-pmid-42351259-2026-07-26-e15d4ad6fca4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42351259." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-42351259-abaloparatide-v1 SHA-256: 29cac77d23a9f395ccb348c6612696a62bfd479d8b43d87193a85d75c6552663.

---

<a id="pubmed-pmid-42498818-abaloparatide-v1"></a>

## PubMed record PMID 42498818

> PeptideScanner retained PubMed bibliographic metadata for PMID 42498818 at 2026-08-10T18:13:56.743Z. PubMed recorded a metadata revision date of 2026-07-24 and an Entrez history date of 2026-07-24. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42498818-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-24
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42498818-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-42498818-abaloparatide-v1
- Content SHA-256: `3273ed8942f27b91c31b2c6e506a5225cc4c52aece9cd828d728fe536def2ba4`

### Claims and source pins

#### Headline

PubMed record PMID 42498818 ([`pubmed-observation-pmid-42498818-2026-07-24-e10c226f7c07`](#source-pubmed-observation-pmid-42498818-2026-07-24-e10c226f7c07))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42498818 at 2026-08-10T18:13:56.743Z. PubMed recorded a metadata revision date of 2026-07-24 and an Entrez history date of 2026-07-24. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42498818-2026-07-24-e10c226f7c07`](#source-pubmed-observation-pmid-42498818-2026-07-24-e10c226f7c07))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42498818 at 2026-08-10T18:13:56.743Z. PubMed recorded a metadata revision date of 2026-07-24 and an Entrez history date of 2026-07-24. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42498818-2026-07-24-e10c226f7c07`](#source-pubmed-observation-pmid-42498818-2026-07-24-e10c226f7c07))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42498818-2026-07-24-e10c226f7c07`](#source-pubmed-observation-pmid-42498818-2026-07-24-e10c226f7c07))

### Sources

<a id="source-pubmed-observation-pmid-42498818-2026-07-24-e10c226f7c07"></a>
- **PubMed record PMID 42498818 · retained source version 1:2026-07-24:current:e10c226f7c073983694510b7380e852cfb9a65f86ccaddfc56a090cab1d422eb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42498818/) (`pubmed-observation-pmid-42498818-2026-07-24-e10c226f7c07`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42498818." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/abaloparatide.json#pubmed-pmid-42498818-abaloparatide-v1 SHA-256: 3273ed8942f27b91c31b2c6e506a5225cc4c52aece9cd828d728fe536def2ba4.

